Author

Michele Riggen

Institution: United BioSource Corporation (United Kingdom)

Observed institution: United BioSource Corporation (United Kingdom)

ORCID: 0009-0008-8159-4109

Observed ORCID: 0009-0008-8159-4109

OpenAlex ID: A5020143735

Evaluating the impact of a Risk Evaluation and Mitigation Strategy with tolvaptan to monitor liver safety in patients with autosomal dominant polycystic kidney disease

2022 · Alvin Estilo, LaRee Tracy, et al. · Clinical Kidney Journal · 22

Five years of post-marketing liver safety data from the tolvaptan Risk Evaluation and Mitigation Strategy

2025 · Emanuel Lohrmann, Thomas Jaeger, et al. · Clinical Kidney Journal · 5

Assessing the effectiveness of the TURALIO (pexidartinib) risk evaluation and mitigation strategy program: patient knowledge, attitudes, and behavior survey (2020–2024)

2026 · Charles Dharmani, Oluwatosin Fofah, et al. · Patient Related Outcome Measures

Works count: 3

Citation count: 27

H-index: 2

I10-index: 1